| 1 |
34651261 | De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials. | 2022 May |
1 |
| 2 |
35001413 | Antiplatelet therapy in cardiovascular disease: Current status and future directions. | 2022 Jun |
1 |
| 3 |
35090983 | Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry. | 2022 Apr 15 |
1 |
| 4 |
35115197 | Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study. | 2022 Jan 31 |
1 |
| 5 |
35294730 | Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention. | 2022 Mar |
1 |
| 6 |
35407624 | A Japanese Dose of Prasugrel versus a Standard Dose of Clopidogrel in Patients with Acute Myocardial Infarction from the K-ACTIVE Registry. | 2022 Apr 4 |
2 |
| 7 |
35428703 | Comparative efficacy and safety of oral P2Y12 inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis. | 2022 Apr |
1 |
| 8 |
35514270 | Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y12 inhibitors. | 2022 May 6 |
1 |
| 9 |
35566604 | Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. | 2022 Apr 28 |
1 |
| 10 |
35621210 | Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. | 2022 Jun 7 |
1 |
| 11 |
33113567 | Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study. | 2021 Apr |
1 |
| 12 |
33309519 | Molecular pharmacology of P2Y receptor subtypes. | 2021 May |
1 |
| 13 |
33412611 | Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. | 2021 Jun |
1 |
| 14 |
33582955 | Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. | 2021 Apr |
1 |
| 15 |
33674980 | NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View. | 2021 Sep |
1 |
| 16 |
33708263 | 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. | 2021 Feb |
1 |
| 17 |
33758122 | Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar. | 2021 Mar 19 |
2 |
| 18 |
33877270 | Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. | 2021 Apr 20 |
2 |
| 19 |
33955698 | Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists. | 2021 Jul |
1 |
| 20 |
33993817 | Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. | 2021 Aug |
1 |
| 21 |
34106029 | Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome. | 2021 Dec |
1 |
| 22 |
34137238 | Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. | 2021 Aug |
1 |
| 23 |
34167672 | Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction. | 2021 Jun 28 |
1 |
| 24 |
34169260 | Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. | 2021 Jun |
1 |
| 25 |
34207339 | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. | 2021 Jun 18 |
1 |
| 26 |
34234079 | Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. | 2021 Jul 8 |
2 |
| 27 |
34242414 | Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. | 2021 Dec |
1 |
| 28 |
34275780 | Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study. | 2021 Oct |
1 |
| 29 |
34319489 | The Function and Regulation of Platelet P2Y12 Receptor. | 2021 Jul 28 |
2 |
| 30 |
34377702 | A Case of Ticagrelor Resistance. | 2021 |
1 |
| 31 |
34664214 | Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis. | 2021 Nov |
1 |
| 32 |
34755215 | Survey of clinical practice pattern in Germany's certified chest pain units : Adherence to the European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndrome. | 2021 Nov 9 |
1 |
| 33 |
34815751 | 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. | 2021 Feb |
1 |
| 34 |
30983087 | Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study. | 2020 Jan |
1 |
| 35 |
31165176 | Aggregometry Response to Half-dose Prasugrel in Flow-diverting Stent Implantation. | 2020 Sep |
1 |
| 36 |
31542850 | Comorbidity and low use of new antiplatelets in acute coronary syndrome. | 2020 Aug |
1 |
| 37 |
32074647 | Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. | 2020 Apr |
1 |
| 38 |
32081368 | Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. | 2020 Apr 15 |
1 |
| 39 |
32152791 | Intensified P2Y12 inhibition for high-on treatment platelet reactivity. | 2020 Oct |
1 |
| 40 |
32272255 | COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. | 2020 Jun |
1 |
| 41 |
32305225 | Meta-Analysis Comparing P2Y12 Inhibitors in Acute Coronary Syndrome. | 2020 Jun 15 |
1 |
| 42 |
32390477 | Prasugrel in the treatment of acute coronary syndrome. | 2020 Nov |
1 |
| 43 |
32513604 | Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2020 Dec |
1 |
| 44 |
32585929 | Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. | 2020 Jun 23 |
1 |
| 45 |
32629976 | New Antithrombotic Drugs in Acute Coronary Syndrome. | 2020 Jun 30 |
1 |
| 46 |
32795098 | Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. | 2020 Aug 4 |
1 |
| 47 |
32821149 | Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence. | 2020 |
1 |
| 48 |
32974447 | Acute thrombosis of everolimus-eluting platinum chromium stent caused by impaired prasugrel metabolism due to cytochrome P450 enzyme 2B6*2 (C64T) polymorphism: a case report. | 2020 Aug |
1 |
| 49 |
33654473 | Acute coronary syndromes with high thrombotic burden: therapeutic innovations. | 2020 Nov |
1 |
| 50 |
33693287 | Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y12 Assay in Patients With Coronary Artery Disease. | 2020 Dec 18 |
1 |